Illumina, Inc. (ILMN)
- Previous Close
81.57 - Open
81.49 - Bid 80.90 x 100
- Ask 81.36 x 100
- Day's Range
80.17 - 82.44 - 52 Week Range
68.70 - 156.66 - Volume
1,272,378 - Avg. Volume
2,488,046 - Market Cap (intraday)
12.84B - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-6.08 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
109.10
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
www.illumina.com8,970
Full Time Employees
December 29
Fiscal Year Ends
Sector
Industry
Recent News: ILMN
View More
Performance Overview: ILMN
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ILMN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ILMN
View MoreValuation Measures
Market Cap
12.91B
Enterprise Value
14.28B
Trailing P/E
--
Forward P/E
18.12
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.99
Price/Book (mrq)
5.45
Enterprise Value/Revenue
3.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-22.27%
Return on Assets (ttm)
4.96%
Return on Equity (ttm)
-23.85%
Revenue (ttm)
4.34B
Net Income Avi to Common (ttm)
-966M
Diluted EPS (ttm)
-6.08
Balance Sheet and Cash Flow
Total Cash (mrq)
1.24B
Total Debt/Equity (mrq)
110.09%
Levered Free Cash Flow (ttm)
381M
Research Analysis: ILMN
View MoreResearch Reports: ILMN
View MoreIllumina Earnings: Tariffs and Negative Chinese Status Weigh on 2025 Outlook
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
RatingPrice TargetLife Science Industry: Tariffs Remain Concerning, but No Major Change to Our Views Currently
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
RatingPrice TargetTariffs Add to Market Uncertainty
The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are United Parcel Service, Inc. (UPS); Elevance Health Inc (ELV); Cisco Systems, Inc. (CSCO); EBay Inc. (EBAY) and the Focus List deletions are Arista Networks Inc (ANET); Illumina Inc (ILMN); Norwegian Cruise Line Hldgs Lt (NCLH); United Airlines Holdings Inc (UAL).
Discounted price offers buying opportunity
Illumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company's products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses. The company's portfolio of products and services is designed to accelerate and simplify genetic analysis. Illumina also invests in startup companies that are pursuing promising genomic-related opportunities. It has roughly 8,970 employees. ILMN shares are included in the S&P 500 index.
RatingPrice Target